HC
NVO

Henshaw Capital’s Novo Nordisk NVO Stock Holding History

Henshaw Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,506
Closed -$1.28M – 292
2025
Q2 		$1.28M Sell
18,506
-4,483
-20% -$305K 0.05% 123
2025
Q1 		$1.6M Buy
22,989
+8,192
+55% +$677K 0.07% 101
2024
Q4 		$1.27M Buy
14,797
+3,094
+26% +$335K 0.05% 105
2024
Q3 		$1.39M Buy
11,703
+8,312
+245% +$1.11M 0.06% 105
2024
Q2 		$484K Buy
3,391
+116
+4% +$15.4K 0.02% 177
2024
Q1 		$421K Sell
3,275
-101
-3% -$12K 0.02% 198
2023
Q4 		$349K Buy
3,376
+436
+15% +$43.1K 0.02% 220
2023
Q3 		$267K Sell
2,940
-776
-21% -$68.4K 0.02% 238
2023
Q2 		$301K Hold
3,716
– – 0.02% 181
2023
Q1 		$296K Sell
3,716
-496
-12% -$35.2K 0.02% 182
2022
Q4 		$285K Sell
4,212
-9,272
-69% -$544K 0.02% 184
2022
Q3 		$672K Buy
13,484
+370
+3% +$19.8K 0.05% 121
2022
Q2 		$731K Sell
13,114
-210
-2% -$11.7K 0.05% 121
2022
Q1 		$740K Hold
13,324
– – 0.04% 131
2021
Q4 		$746K Sell
13,324
-4,928
-27% -$267K 0.04% 131
2021
Q3 		$876K Buy
18,252
+654
+4% +$31.6K 0.05% 114
2021
Q2 		$737K Hold
17,598
– – 0.05% 132
2021
Q1 		$593K Hold
17,598
– – 0.04% 149
2020
Q4 		$615K Sell
17,598
-1,644
-9% -$56.8K 0.05% 136
2020
Q3 		$668K Buy
19,242
+5,236
+37% +$175K 0.05% 126
2020
Q2 		$459K Buy
14,006
+1,146
+9% +$36.6K 0.04% 153
2020
Q1 		$387K Buy
12,860
+5,506
+75% +$164K 0.04% 166
2019
Q4 		$213K Buy
+7,354
New +$204K 0.02% 257
2016
Q4 		– Sell
-12,542
Closed -$261K – 283
2016
Q3 		$261K Sell
12,542
-6,056
-33% -$150K 0.03% 228
2016
Q2 		$500K Hold
18,598
– – 0.07% 115
2016
Q1 		$504K Buy
+18,598
New +$498K 0.07% 118

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Henshaw Capital's NVO Position: Q3 2025 in Review

Henshaw Capital sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 18,506 shares — an estimated $1.28M sold.

Henshaw Capital first reported a position in NVO in Q1 2016 and held it in 26 quarters. The position peaked at $1.6M in Q1 2025. 1,398 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Henshaw Capital reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Henshaw Capital sold 18,506 Novo Nordisk shares in Q3 2025, an estimated $1.28M.
  • Henshaw Capital first reported a position in Novo Nordisk in Q1 2016 and held it in 26 quarters.
  • Henshaw Capital's Novo Nordisk position peaked at $1.6M in Q1 2025.
  • 1,398 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Henshaw Capital's 13F filing for Q3 2025, filed 28 May 2026.